Search results for " herpes zoster"

showing 5 items of 5 documents

Preventing and managing herpes zoster: key actions to foster healthy aging

2015

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can prot…

Gerontologymedicine.medical_specialtyPopulation ageingAgingSettore MED/17 - Malattie InfettiveImmunosenescenceCost-Benefit AnalysisHerpes zosterAlternative medicinePsychological interventionSocio-culturaleDiseaseSettore MED/42 - Igiene Generale E ApplicataQuality of life (healthcare)medicineHerpes Zoster VaccineHumansHerpes zoster; Immunosenescence; Vaccine; Aged; Cost-Benefit Analysis; Herpes Zoster; Herpes Zoster Vaccine; Humans; Italy; Middle Aged; Quality of Life; Aging; Vaccination; Aging; Geriatrics and GerontologyAgedbusiness.industryTetanusVaccinationHerpes zoster; Immunosenescence; Vaccine; Aging; Geriatrics and GerontologyMiddle Agedmedicine.diseaseComorbidityVaccinationItalyQuality of LifeGeriatrics and GerontologybusinessVaccineVaccine; Herpes zoster;Immunosenescence
researchProduct

[Herpes Zoster and its prevention in Italy. Scientific consensus statement].

2014

In this paper, an Italian group of experts presents a revision of the available data about epidemiology and prevention of Herpes Zoster (HZ). HZ is an acute viral diseases caused by the reactivation of Varicella Zoster Virus (VZV). HZ is characterized by neurological and dermatological symptoms with a dermatomeric localization. The reactivation of the virus from the latent status in the sensitive ganglia increases with age and failing cell mediated immunity. In Europe, more than 95% of adults presents antibodies against VZV. Incidence of HZ is similar all over the world, related to the age of the population: from 2-3/1000 persons/year in the age group 20 to 50 years to 5/1000 in the 60 year…

AdultAged 80 and overClinical Trials as TopicEvidence-Based MedicineSettore MED/17 - Malattie InfettiveIncidenceSocio-culturaleNeuralgia Postherpeticconsensus statementMiddle AgedSettore MED/42 - Igiene Generale E ApplicataHerpes ZosterAge DistributionItalyRisk Factors80 and overNeuralgiaHerpes Zoster VaccineHumansAdult; Age Distribution; Aged; Aged 80 and over; Clinical Trials as Topic; Evidence-Based Medicine; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Italy; Middle Aged; Neuralgia Postherpetic; Risk Factors; SicilyPostherpeticSicilyprevention of herpes zosterAgedIgiene e sanita pubblica
researchProduct

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review

2019

Background Vaccine adjuvants are compounds that significantly enhance/prolong the immune response to a co-administered antigen. The limitations of the use of aluminium salts that are unable to elicite cell responses against intracellular pathogens such as those causing malaria, tuberculosis, or AIDS, have driven the development of new alternative adjuvants such as QS-21, a triterpene saponin purified from Quillaja saponaria. Purpose The aim of this review is to attempt to clarify the mechanism of action of QS-21 through either receptors or signaling pathways in vitro and in vivo with special emphasis on the co-administration with other immunostimulants in new adjuvant formulations, called a…

InflammasomesT-Lymphocytesmedicine.medical_treatmentHerpes zosterPharmaceutical ScienceMonophosphoryl Lipid AAPCs antigen presenting cellsMiceCMI cell mediated immunity0302 clinical medicineDrug DiscoveryHerpes Zoster VaccineMedicineNSCLC non small cell lung carcinomaCancerImmunity CellularVaccines Synthetic0303 health sciencesImmunogenicityIl-2 interleukine 2HIV human immunodeficiency virusLipid A030220 oncology & carcinogenesisCytokinesMolecular MedicineDCs dendritic cellsNK natural killerAdjuvantTLR Toll-like receptorHerpes Zoster VaccineCD cluster of differentiationAntigen-Presenting CellsCTL cytotoxic T lymphocytesHZ herpes zosterMPL 3-deacylated monophosphoryl lipidVaccine adjuvantImmunoadjuvantArticleVZV varicella zoster virus03 medical and health sciencesImmune systemAdjuvants ImmunologicAntigenPAMPs pathogen-associated molecular patternsMalaria VaccinesPRRs pathogen recognition receptorsQS-21 Quillaja saponaria Molina-fraction 21AnimalsMHC major histocompatibility complexMtb Mycobacterium tuberculosis bacteriaSARS severe acute respiratory syndromeAntigen-presenting cellIFN-γ interferon-gamma030304 developmental biologyPharmacologybusiness.industryA-β amyloid-betaTNF-α tumor necrosis factor-alphaSaponinsQS-21MalariaQuillaja saponariaComplementary and alternative medicineTCR T-cell receptorLiposomesImmunologyKLH keyhole limpet hemocyaninbusinessdLN draining lymph nodesMAPK mitogen activated protein kinasePhytomedicine
researchProduct

Multidimensional Frailty and Vaccinations in Older People: A Cross-Sectional Study

2022

It is known that influenza, herpes zoster, pneumococcal and pertussis infections may increase morbidity and mortality in older people. Vaccinations against these pathogens are effective in older adults. Frailty seems to be an important determinant of vaccination rates, yet data supporting this association are still missing. Therefore, we aimed to investigate the prevalence of four recommended vaccinations (influenza, herpes zoster, pneumococcal and diphtheria-tetanus-pertussis) and the association with multidimensional frailty assessed using a self-reported comprehensive geriatric assessment tool, i.e., the multidimensional prognostic index (SELFY-MPI). Older participants visiting the outpa…

PharmacologySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/09 - Medicina InternapneumococcuImmunologydiphtheria-tetanus-pertussisherpes zostermultidimensional prognostic index; vaccination; influenza; herpes zoster; pneumococcus; diphtheria-tetanus-pertussisvaccinationSettore MED/42 - Igiene Generale E Applicatamultidimensional prognostic indexdiphtheria-tetanus-pertussivaccination.Infectious DiseasesDrug DiscoveryPharmacology (medical)diphtheria-tetanus-pertussis; herpes zoster; influenza; multidimensional prognostic index; pneumococcus; vaccinationinfluenzapneumococcusVaccines; Volume 10; Issue 4; Pages: 555
researchProduct

Localizzazione S1 di Herpes Zooster: un raro caso di ritenzione urinaria.

2011

Donna di 46 anni con ritenzione urinaria acuta e stipsi. Presentava piccola vescicola sul dorso del piede sinistro quale unica manifestazione di localizzazione di virus Herpes Zooster a livello sacrale S1. Viene riportato l'esame urodinamico e le risultanze dei test sierologici seriati specifici per l'infezione da virus Varicella Zooster. La paziente è guarita a seguito di terapia specifica con Acyclovir. Il caso riportato dimostra che anche il segmento sacrale S1 contribuisce al controllo della dinamica minzionale

Settore MED/07 - Microbiologia E Microbiologia ClinicaRitenzione d'urina Localizzazione S1 Herpes ZosterSettore MED/26 - NeurologiaSettore MED/24 - Urologia
researchProduct